Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mRNA Vaccines for Influenza: Hope for a Universal Vaccine?

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Mosaic Inverted Hemagglutinin Extracellular Vesicle Vaccines Elicit Protective Systemic and Mucosal Immunity against Heterosubtypic Influenza Infection.

ACS nano·2026
Same author

Type I interferon signaling is required for resistance to primary influenza virus infection and vaccine-induced long-term immunity.

Journal of virology·2026
Same author

Mature Dendritic Cell-Derived Extracellular Vesicles are Potent Mucosal Adjuvants for Influenza Hemagglutinin Vaccines.

ACS nano·2025
Same author

Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination.

Journal of virology·2025
Same author

Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice.

Nanoscale horizons·2024

Related Experiment Video

Updated: Oct 5, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

12.8K

Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice.

Chunhong Dong1, Ye Wang1, Wandi Zhu1

  • 1Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, Atlanta, Georgia 30303, United States.

ACS Applied Materials & Interfaces
|January 27, 2022
PubMed
Summary

Intranasal influenza vaccines using polyethylenimine (PEI) nanoparticles with hemagglutinin (HA) and CpG adjuvants show promise. These PEI-HA/CpG nanoparticles enhance immune responses and provide cross-protection against influenza.

Keywords:
cross-protectioninfluenza vaccineintranasal vaccinationpolyethyleniminerecombinant protein vaccine

More Related Videos

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.5K
Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity
07:15

Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity

Published on: November 22, 2021

2.5K

Related Experiment Videos

Last Updated: Oct 5, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

12.8K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.5K
Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity
07:15

Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity

Published on: November 22, 2021

2.5K

Area of Science:

  • Immunology
  • Nanotechnology
  • Vaccinology

Background:

  • The intranasal (i.n.) route is optimal for respiratory disease vaccines.
  • Polycationic polyethylenimine (PEI) can form nanoparticles with viral glycoproteins.

Purpose of the Study:

  • To fabricate and evaluate PEI-HA and PEI-HA/CpG nanoparticles for i.n. influenza vaccination.
  • To investigate their immunogenicity, protective efficacy, and immune response profiles.

Main Methods:

  • Fabrication of PEI-hemagglutinin (HA) and PEI-HA/CpG nanoparticles.
  • Intranasal vaccination regimen in mice.
  • Assessment of immune responses, including antibody production and cellular immunity.
  • Evaluation of heterologous cross-protection.

Main Results:

  • Nanoparticles significantly enhanced HA immunogenicity and provided cross-protection.
  • PEI-HA/CpG nanoparticles induced robust, balanced IgG1/IgG2a responses with enhanced neutralization and ADCC.
  • Both local and systemic cellular immunity were augmented and sustained for six months.
  • PEI and CpG demonstrated synergistic effects on immune responses.

Conclusions:

  • PEI-HA/CpG nanoparticles represent a potential cross-protective influenza vaccine candidate.
  • Polycationic PEI nanoplatforms are promising for mucosal vaccine development.